Procedural results for percutaneous coronary intervention (PCI) in coronary vessels with chronic total occlusion (CTO) have improved in recent years, and PCI strategies have moved toward more complete revascularization with more liberal use of CTO-PCI. However, evidence evaluating CTO-PCI is limited to observational studies and small clinical trials.
C
hronic total occlusion (CTO) of a coronary artery is relatively common, but strategies for its treatment have been inconsistent. 1, 2 Coronary artery bypass surgery has been preferred in patients with severe coronary artery disease (CAD) including a CTO. 3 In contrast, CTO of 1 major epicardial coronary artery without other coronary stenoses has traditionally been treated conservatively because of the uncertain benefits and technical challenges of percutaneous coronary intervention (PCI). [4] [5] [6] In patients with multivessel CAD including a CTO, stenting obstructive non-CTO lesions while treating the CTO medically has been an alternative strategy in real-world practice. 5, 7 Advances in devices and treatment algorithms and growing experience have increased technical success of CTO-PCI in recent years. [8] [9] [10] In addition, several studies have suggested improved symptoms or survival with CTO-PCI, supporting the theoretical argument that PCI effectively relieves ischemia in myocardium subtended by the CTO vessel. [11] [12] [13] Accordingly, the treatment strategy for patients with CTO has moved toward complete revascularization with more liberal use of CTO-PCI. However, most data suggesting a benefit of CTO-PCI were derived from observational studies that compared patients who experienced successful PCI to those who experienced a failed procedure, without a consistent strategy on non-CTO vessels. Indeed, other studies have suggested limited clinical benefit from CTO-PCI. [14] [15] [16] [17] To address this issue, we designed the DECISION-CTO trial (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion) to compare the effect of CTO-PCI versus no CTO-PCI, with a background of medical therapy and PCI of obstructive non-CTO lesions in both groups. The trial was terminated early because of slow patient recruitment.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Overview
The DECISION-CTO trial was an open-label, multicenter, randomized controlled trial that was conducted at 19 sites in the Asian countries of Korea, India, Indonesia, Thailand, and Taiwan. An annual volume of at least 500 PCIs with a presence of a CTO operator was a prerequisite for each study center. Investigators affiliated with the Heart Institute at Asan Medical Center, Seoul, South Korea, designed the study, collected and managed the data, and performed the statistical analyses. The study protocol was approved by the institutional review board at each participating center, and each patient provided written informed consent.
Eligible patients were men and women at least 18 years old who presented with silent ischemia, stable angina, or acute coronary syndrome. Patients with a de novo CTO located in a proximal to midepicardial coronary artery with a reference vessel diameter of ≥2.5 mm were enrolled. CTO was defined as a coronary artery obstruction with Thrombolysis in Myocardial Infarction flow grade 0 of at least 3 months' duration based on the patient's history. When no definite evidence of occlusion duration existed, the diagnosis of CTO was made based on angiographic morphology by at least 2 experienced interventional cardiologists working at each center. 18, 19 Patients with a CTO located in a distal coronary artery, 3 different vessel CTOs at any location, 2 proximal CTOs in separate coronary arteries, or a CTO in the left main segment, in-stent restenosis, or graft vessel were excluded. Patients with ST-segment-elevation myocardial infarction (MI) requiring primary PCI, those with complex CAD who were considered more appropriate for bypass surgery, and those who were deemed to have a high procedural risk, including those with a serum creatinine value ≥2.0 mg/dL or left ventricular ejection fraction <30% at baseline, were also excluded.
The DECISION-CTO trial was a noninferiority study, hypothesizing that the efficacy of no CTO-PCI strategy is not inferior to the CTO-PCI strategy for the treatment of CAD accompanied by CTO. For the sample size calculation, we assumed that the 3-year rate of the primary composite end point in the CTO-PCI group would be 17% based on a previously published report. 20 Using a noninferiority margin of 0.7 of the 3-year event rate ratio (rate of the no CTO-PCI group/rate of the CTO-PCI group) for the lower boundary of the 97.5% confidence interval with 5% lost to follow-up, we estimated that with a total of 1284 patients, the study would have 80% power to show noninferiority, with a 1-sided type I error rate
Clinical Perspective
What Is New?
• Chronic total occlusion (CTO)-percutaneous coronary intervention (PCI) did not reduce the 4-year risk of major adverse cardiovascular events in patients with PCI-eligible, de novo coronary CTOs.
• These findings should be interpreted with the caveats that nearly 20% of patients in the no CTO-PCI group crossed over to CTO-PCI within 3 days after randomization and that the study was stopped early because of slow enrollment.
• Both study groups (CTO-PCI and no CTO-PCI) were associated with substantial quality of life improvements that were sustained through 36 months, with no differences between groups in the primary quality of life analyses.
What Are the Clinical Implications?
• 
Randomization
After anatomic assessment of CAD by diagnostic coronary angiography, eligible patients were randomized in a 1:1 ratio using an interactive web response system to receive either PCI or no PCI for the qualifying CTO lesion. All patients were to receive guideline-directed medical therapy and PCI for obstructive non-CTO lesions. The allocation sequence was computer-generated and stratified according to the study center, location of CTO, and presence or absence of diabetes mellitus, with random block sizes of 4 or 6.
Procedures and Medications
For patients assigned to the CTO-PCI strategy, CTO-PCI was to be performed within 30 days after randomization. In the case of procedural failure, an additional attempt was allowed within 30 days after the first attempt. The use of specialized devices or techniques and the choice of the drug-eluting stent type were left to the operator's discretion. Successful CTO-PCI was defined as restoration of Thrombolysis in Myocardial Infarction flow grade 3 with residual stenosis <30%, as determined by the operator. Study patients were not restricted to those who had isolated CTO disease; thus, the trial also involved revascularizations for obstructive non-CTO lesions. For patients with multivessel CAD, regardless of random treatment assignment, PCI was recommended for all obstructive (diameter stenosis ≥50% for left main and ≥70% for nonleft main CAD) non-CTO lesions within a vessel diameter ≥2.5 mm. In the CTO-PCI strategy arm, the treatment sequence of CTO and non-CTO lesions was decided by the operator, taking into consideration the safety of the procedure. Identical types of drug-eluting stent were recommended for all CTO and non-CTO lesions in a single patient at the index treatment and at any revascularization procedures during follow-up.
Pharmacological treatments had to be optimized early after randomization in accordance with the clinical guidelines and established standards of practice. 21, 22 Patients were prescribed daily aspirin and statin. β-Blockers, calcium channel blockers, or long-acting nitrates, alone or in combination, were used as anti-ischemic therapy. An angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker was considered for secondary prevention. Patients undergoing stent implantation received a P2Y12 receptor inhibitor for at least 12 months in addition to standard medical therapy. Blood pressure and diabetic control were emphasized. Patients received counseling about smoking cessation, weight control, and regular exercise.
Study End Points and Follow-Up
The primary end point of the trial was a composite of death from any cause, MI, stroke, or any revascularization. Secondary outcomes included the individual components of the primary outcome, as well as bleeding, stent thrombosis, and health-related quality of life (QOL). Detailed definitions of end points and additional secondary end points are listed in the Appendix in the online-only Data Supplement. Any subsequent PCI or bypass surgery after the index procedure performed in both study arms was regarded as a primary end point event. However, cases of patients assigned to the no CTO-PCI strategy who received a staged CTO-PCI early after the study enrollment (all within 3 days in this trial) were considered protocol deviations rather than events. This decision was made because the trial examined the effect of complete (opening the CTO) versus incomplete (leaving the CTO unopened) revascularization intended around the time of the randomization. Study monitors collected source documents of all primary and secondary end point events for adjudication by an independent events committee. The extent of CAD and the SYNTAX score (Synergy Between PCI With TAXUS and Cardiac Surgery) were assessed at the angiographic core laboratory. CTO lesion complexity was evaluated by calculating the Japanese-CTO score for each case. 23 Health-related quality of life was assessed at baseline and at 1, 6, 12, 24, and 36 months with the use of the visual analogue scale of European Quality of Life-5 Dimensions score and the Seattle Angina Questionnaire. 24, 25 Clinical follow-up assessments were performed via clinic visits or telephone interviews at 30 days, 6 and 12 months, and annually thereafter. Data quality was monitored systematically, because the research team in the Data Coordinating Center in the CardioVascular Research Foundation periodically visited all participating centers and performed monitoring through source document verification of the informed consent form, enrollment criteria, and main outcomes in all patients.
Statistical Analysis
Time-to-event outcomes were determined from the date of randomization to the final follow-up date. Cumulative event rates and survival curves were generated using the KaplanMeier method. The noninferiority hypothesis was assessed with the use of a z-test. Cox proportional hazards regression analyses were conducted to estimate the risk associated with CTO-PCI strategy relative to that of no CTO-PCI strategy. Secondary analysis for primary outcome was conducted in several clinically relevant subgroups with tests for interactions.
Analyses of QOL data were restricted to patients who had data both at baseline and at each time point of interest. To evaluate the changes in QOL, within-group comparisons for each health status scale were performed between baseline and each follow-up time point using paired Student t tests. Differences in QOL measures between CTO-PCI and no CTO-PCI strategy at each time point were estimated using randomeffect growth curve models, which accounted for missing data under the missing-at-random assumption. Covariates for the models included treatment group, follow-up time, interactions between treatment and time, and baseline clinical factors (age, sex, hypertension, diabetes mellitus, previous stroke, heart failure, renal dysfunction, clinical presentation, location of CTO, and SYNTAX score category). In addition, quadratic and cubic terms of time along with their interactions with treatment group were included in the models to account for ORIGINAL RESEARCH ARTICLE nonlinear trends. Data analyses were performed using "survival," "cmprsk," and "lme4" packages in R software version 3.2.2 13 (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org). Statistical hypothesis tests with P <0.05 were considered significant.
RESULTS

Patients and Procedures
Between March 2010 and October 2016, 834 patients were randomly assigned to a treatment group. After exclusion of 19 patients who withdrew consent, 417 patients were assigned to the CTO-PCI strategy, and 398 patients were randomly assigned to the no CTO-PCI strategy. Final follow-up status was ascertained between August and September 2017, and the 3-year follow-up was complete in 89.9% and 92.1% of the eligible patients in the CTO-PCI and no CTO-PCI groups, respectively (Figure I in the online-only Data Supplement).
Baseline patient and lesion characteristics were well balanced between the 2 treatment groups ( Table 1 ). The mean patient age was 62.5±10.0 years, and 82.5% of patients were men, 33.1% had diabetes mellitus, and 73.4% had multivessel CAD. CTOs were located in the left anterior descending artery in 43.3% of patients, right coronary artery in 46.3%, and left circumflex artery in 10.4%. The overall mean SYNTAX score was 20.8±9.3, and the mean Japanese-CTO score for CTO lesions was 2.1±1.2, without between-group differences. Averages of 1.24±1.04 and 1.29±0.99 (P=0.49) obstructive non-CTO lesions were present at a total of 427 and 417 non-CTO vessels in the CTO-PCI and no CTO-PCI group, respectively. Among the 417 patients assigned to the CTO-PCI strategy, PCI for a CTO lesion was attempted in 384 patients at a median time of 1 day (interquartile range, 0 to 7 days). Of those, the procedure was successful in 348 patients (90.6%). Among the 398 patients assigned to the no CTO-PCI strategy, 313 remained in their assigned group, whereas 78 (19.6%) immediately crossed over to CTO-PCI (median 1 day [interquartile range, 1 to 2 days], successful in 73, failed in 5). Details on treatment flow, crossovers, and final treatments are depicted in Figure 1 . The most common reason for crossover from no CTO-PCI to CTO-PCI strategy was the investigator's intention to control the patient's symptom (26 patients, 24.3%) ( Table I in the onlineonly Data Supplement). Characteristics of participants who crossed over between groups are shown in Table II in the online-only Data Supplement.
Procedural details for both groups are summarized in Tables III and IV in the online-only Data Supplement. Overall, the retrograde approach was used in 24.6% of the patients who actually underwent attempted CTO-PCI. The overall success rate was 91%, and an average of 2.3 stents with a length of 68.2 mm was used for the target CTO lesion. Serious nonfatal complications associated with CTO-PCI occurred in 3 patients (1 stroke, 1 cardiac tamponade, and 1 patient with recurrent episodes of ventricular tachyarrhythmia induced by intracoronary thrombus). In both groups, about half of the patients underwent PCI, for an average of 1.3 non-CTO lesions. The total number of stents used for non-CTO lesions were higher in the no CTO-PCI group (1.5±0.9 The data are presented as n (%) or means (SD), unless otherwise stated. CTO indicates chronic total occlusion; J-CTO, Japanese-chronic total occlusion; PCI, percutaneous coronary intervention; and SYNTAX, Synergy Between PCI With TAXUS and Cardiac Surgery. *Complete data were available for 413 patients in the CTO-PCI group and 391 patients in the no CTO-PCI group, which were the denominators of the percentages.
†Renal dysfunction was defined as an estimated glomerular filtration rate <60 mL·min 
42).
The medications that the patients were taking at baseline and during follow-up are summarized in Table  V in the online-only Data Supplement. Compared to patients in the no CTO-PCI group, those in the CTO-PCI group were more likely to receive antiplatelet agents, including aspirin or P2Y12 receptor inhibitors. However, the use of other secondary preventive or antianginal medications was similar between the 2 groups.
Primary and Secondary End Points
The median duration of follow-up was 4.0 years (interquartile range, 2.4 to 5.1 years) in both groups. The results of the analyses of the primary and hierarchical secondary end points are provided in Table 2 . During follow-up, the primary end point occurred in 93 patients (22.3%) in the CTO-PCI group and 89 patients (22.4%) in the no CTO-PCI group (hazard ratio, 1.03; 95% CI, 0.77 to 1.37; P=0.86; 3-year event rate ratio, 1.02; lower limit of 1-sided 97.5% CI, 0.755; P=0.014 for noninferiority; Figure 2 ). The post hoc power of the study given the number of patients enrolled was 63.6%, and it was 94.1% if the observed event rate is taken into consideration. There was no difference between the CTO-PCI and no CTO-PCI groups with regard to individual outcomes of death, MI, stroke, revascularization, or any composite secondary outcomes. The subsequent revascularization rate between the two strategies was not different for both the CTO vessels and the non-CTO vessels. Bleeding, mostly access-site bleeding, was more frequent in the CTO-PCI group than in the no CTO-PCI group (37.4% versus 13.6%; hazard ratio, 3.18; 95% CI, 2.33 to 4.33; P<0.001). However, the rate of major bleeding was not significantly different between the two groups (1.8% versus 1.7%; hazard ratio, 1.15; 95% CI, 0.40 to 3.28; P=0.80). Definite stent thrombosis occurred in 4 patients: 1 in a stent placed in the CTO segment and 3 in stents placed in non-CTO vessels. The results of secondary and subgroup analysis are shown in Table VI 
Health-Related Quality of Life
The overall rate of response for QOL assessments among surviving patients was 76.4% at baseline, 65.2% at 1 year, 61.7% at 2 years, and 59.0% at 3 years. Changes in mean scores on the QOL scales at each follow-up time point are summarized in Table  VII and Supplemental Figure V in the online-only Data Supplement. At 1 month, the scores had increased substantially from baseline in both groups for all domains of the QOL questionnaire but generally increased to a larger extent in the CTO-PCI arm compared to the no CTO-PCI arm. These improvements in scores in each group were largely maintained by 12 and 36 months. 
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Between-group differences in QOL measures over time are summarized in Table 3 and Table VIII in the onlineonly Data Supplement. Overall, there was no significant difference in the mean scores between the treatment strategies on any of the QOL scales.
DISCUSSION
DECISION-CTO involved patients with PCI-eligible, de novo coronary CTO and compared the effect of 2 treatment strategies: PCI versus no PCI on CTO lesions with the option for PCI of non-CTO lesions. The study was limited by large numbers of protocol violations, with almost 20% crossover from no CTO-PCI to CTO-PCI. The study was also terminated early because of slow enrollment. There was no significant difference between the CTO-PCI and the no CTO-PCI strategy with respect to the composite primary end point of death, MI, stroke, or any revascularization throughout a median of 4-year follow-up period. Both CTO-PCI and no CTO-PCI strategy were associated with significant improvements, but without between-group differences, in disease-specific Hazard ratios are for patients with CTO-PCI strategy relative to that of no CTO-PCI strategy. CTO indicates chronic total occlusion; HR, hazard ratio; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
*Number and percentages are crude rates. 
No. at Risk
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health status that were sustained through 36 months. CTO-PCI was associated with higher overall bleeding rates, but major bleeding was rare and not different between the two groups. Several features of the trial design and enrolled patients should be acknowledged. First, the trial design involved not only the comparison of an initial strategy for a CTO lesion but also treatment for non-CTO lesions. The trial did not intend to compare the pure treatment effect of PCI versus no PCI for a given CTO. More than 70% of patients had multivessel CAD, and nearly half of patients in both groups received PCI for non-CTO lesions. Although the rate of complete revascularization and residual SYNTAX score in non-CTO vessels was similar for both groups, this complex situation deserves consideration, particularly when interpreting the health status data. Second, patients enrolled in our trial may have had a relatively lower risk of future cardiovascular events (ie, 25% of patients had singlevessel disease comprising only a CTO, SYNTAX score was relatively low, and most patients had a normal left ventricular ejection fraction). Third, the trial was led by high-volume centers with expertise on CTO-PCI, 2 of them actively recruiting >60% of the total patients. The success rate of CTO-PCI was high (≈90%), whereas the rate of associated serious complications was low (<1%). Thus, we acknowledge that the particulars of clinical practice in the institutions in this trial, as well as the specific expertise of the interventional cardiologists who performed the procedures, may differ from those of other institutions and practitioners, potentially limiting the generalizability of these results in other settings.
In our trial, the rate of the primary end point of death, MI, stroke, or any revascularization was not significantly different between the no CTO-PCI strategy and the CTO-PCI strategy. Given the limitations of study conduct, including high rates of crossover and early study termination, these null findings must be interpreted with caution. Further large-scale randomized trials are needed to address the impact of CTO-PCI on ischemia, clinical outcomes, and quality of life.
Somewhat unexpectedly, there was substantial and rapid improvement in early health status scores among the patients in both groups, potentially limiting the ability of the study to evaluate difference in QOL between the two strategies at later time points in our longitudinal analyses. Because baseline health status assessments were done before any intervention, this observation indicates that PCI for non-CTO lesions may have had considerable influence in both groups. The EURO-CTO trial evaluated QOL among patients whose symptoms were deemed to be truly attributed to CTO and showed superiority of CTO-PCI over no CTO-PCI. 26 This study had several limitations. First, the early termination of the trial reduced its statistical power, which warrants cautious interpretation of the study results. Under the same assumptions as for the original sample size calculation, the study would retain 64% power for the original primary analysis with our given sample size. Second, the high number of crossovers in the no CTO-PCI group limits conclusions drawn from the intention-to-treat analysis and may have led to an underestimation of the true effect of CTO-PCI strategy. Third, the response rate of the QOL questionnaire was low; thus, the results may have been potentially biased. Also, the lack of sham control may have introduced a chance of a placebo effect in the treatment group. Fourth, a viability test was not mandatory for patient enrollment in our trial. Concerns exist because reopening a CTO vessel supplying nonviable territories would be unlikely to improve prognosis. Nearly 60% of the study patients underwent a noninvasive stress test at baseline in our trial, but only 272 patients underwent a myocardial perfusion scan. However, the majority of patients enrolled in this study had preserved left ventricular function on echocardiography, and 95% of patients who underwent a perfusion scan showed inducible ischemia in the CTO-related territory without between-group differences. The prognosis may differ based on the amount of myocardium at risk that is subtended by the CTO vessel, and this should be a subject of investigation. 27 Higher-risk patients with more complex CTOs must also be tested to define the prognostic role of CTO-PCI in the future, but investigators should be cautious because PCI failures, unexpected complications, and crossovers may occur more frequently.
In conclusion, our trial demonstrated no significant difference in the primary end point of death, MI, stroke, or any revascularization with CTO-PCI versus no CTO-PCI over the course of 4 years. Both the CTO-PCI and no CTO-PCI groups showed substantial QOL improvements that were sustained through 36 months. Future large-scale studies are needed to study the role of CTO-PCI, with careful attention to prevent crossover between groups.
